Menin inhibitors in the treatment of acute myeloid leukemia

2.

Hanahan

D

,

Weinberg

RA

.

Hallmarks of cancer: the next generation

.

Cell

.

2011

;

144

(

5

):

646

-

674

.

3.

Cancer Genome Atlas Research Network

,

Ley

TJ

,

Miller

C

, et al.

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia

.

N Engl J Med

.

2013

;

368

(

22

):

2059

-

2074

.

4.

Jones

PA

,

Baylin

SB

.

The epigenomics of cancer

.

Cell

.

2007

;

128

(

4

):

683

-

692

.

5.

Silverman

LR

,

Holland

JF

,

Weinberg

RS

, et al.

Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes

.

Leukemia

.

1993

;

7

(

suppl 1

):

21

-

29

.

6.

Jüttermann

R

,

Li

E

,

Jaenisch

R

.

Toxicity of 5-aza-2’-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

.

Proc Natl Acad Sci U S A

.

1994

;

91

(

25

):

11797

-

11801

.

7.

Fenaux

P

,

Mufti

GJ

,

Hellstrom-Lindberg

E

, et al.

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

.

Lancet Oncol

.

2009

;

10

(

3

):

223

-

232

.

8.

Dombret

H

,

Seymour

JF

,

Butrym

A

, et al.

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

.

Blood

.

2015

;

126

(

3

):

291

-

299

.

9.

Kantarjian

H

,

Oki

Y

,

Garcia-Manero

G

, et al.

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

.

Blood

.

2007

;

109

(

1

):

52

-

57

.

10.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

11.

Montesinos

P

,

Recher

C

,

Vives

S

, et al.

Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia

.

N Engl J Med

.

2022

;

386

(

16

):

1519

-

1531

.

12.

Lübbert

M

,

Wijermans

PW

,

Kicinski

M

, et al.

10-Day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

.

Lancet Haematol

.

2023

;

10

(

11

):

e879

-

e889

.

13.

Marks

PA

,

Rifkind

RA

,

Richon

VM

,

Breslow

R

,

Miller

T

,

Kelly

WK

.

Histone deacetylases and cancer: causes and therapies

.

Nat Rev Cancer

.

2001

;

1

(

3

):

194

-

202

.

14.

Dawson

MA

,

Kouzarides

T

,

Huntly

BJP

.

Targeting epigenetic readers in cancer

.

N Engl J Med

.

2012

;

367

(

7

):

647

-

657

.

15.

Perner

F

,

Armstrong

SA

.

Targeting chromatin complexes in myeloid malignancies and beyond: from basic mechanisms to clinical innovation

.

Cells

.

2020

;

9

(

12

):

2721

.

16.

Garcia-Manero

G

,

Podoltsev

NA

,

Othus

M

, et al.

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

.

Leukemia

.

2024

;

38

(

1

):

58

-

66

.

17.

Yokoyama

A

,

Cleary

ML

.

Menin critically links MLL proteins with LEDGF on cancer-associated target genes

.

Cancer Cell

.

2008

;

14

(

1

):

36

-

46

.

18.

El Ashkar

S

,

Schwaller

J

,

Pieters

T

, et al.

LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

.

Blood

.

2018

;

131

(

1

):

95

-

107

.

19.

Feng

Z

,

Ma

J

,

Hua

X

.

Epigenetic regulation by the menin pathway

.

Endocr Relat Cancer

.

2017

;

24

(

10

):

T147

-

T159

.

20.

Brunetti

L

,

Gundry

MC

,

Sorcini

D

, et al.

Mutant NPM1 maintains the leukemic state through HOX expression

.

Cancer Cell

.

2018

;

34

(

3

):

499

-

512.e9

.

21.

Woolthuis

CM

,

Han

L

,

Verkaik-Schakel

RN

, et al.

Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells

.

Leukemia

.

2012

;

26

(

4

):

848

-

853

.

22.

Falini

B

,

Mecucci

C

,

Tiacci

E

, et al.

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

.

N Engl J Med

.

2005

;

352

(

3

):

254

-

266

.

23.

Uckelmann

HJ

,

Haarer

EL

,

Takeda

R

, et al.

Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia

.

Cancer Discov

.

2023

;

13

(

3

):

746

-

765

.

24.

Wang

XQD

,

Fan

D

,

Han

Q

, et al.

Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia

.

Cancer Discov

.

2023

;

13

(

3

):

724

-

745

.

25.

Issa

GC

,

Zarka

J

,

Sasaki

K

, et al.

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

.

Blood Cancer J

.

2021

;

11

(

9

):

162

.

26.

Döhner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

27.

Yokoyama

A

,

Somervaille

TCP

,

Smith

KS

,

Rozenblatt-Rosen

O

,

Meyerson

M

,

Cleary

ML

.

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis

.

Cell

.

2005

;

123

(

2

):

207

-

218

.

28.

Grembecka

J

,

He

S

,

Shi

A

, et al.

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia

.

Nat Chem Biol

.

2012

;

8

(

3

):

277

-

284

.

29.

Borkin

D

,

He

S

,

Miao

H

, et al.

Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo

.

Cancer Cell

.

2015

;

27

(

4

):

589

-

602

.

30.

Kuhn

MW

,

Song

E

,

Feng

Z

, et al.

Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia

.

Cancer Discov

.

2016

;

6

(

10

):

1166

-

1181

.

31.

Klossowski

S

,

Miao

H

,

Kempinska

K

, et al.

Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia

.

J Clin Invest

.

2020

;

130

(

2

):

981

-

997

.

32.

Krivtsov

A V

,

Evans

K

,

Gadrey

JY

, et al.

A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia

.

Cancer Cell

.

2019

;

36

(

6

):

660

-

673.e11

.

33.

Uckelmann

HJ

,

Kim

SM

,

Wong

EM

, et al.

Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia

.

Science (1979)

.

2020

;

367

(

6477

):

586

-

590

.

34.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

35.

Issa

GC

,

Aldoss

I

,

Thirman

MJ

, et al.

Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)

.

J Clin Oncol

.

2025

;

43

(

1

):

75

-

84

.

36.

Zeidner

J

,

Lin

T

,

Welkie

R

, et al.

Phase 1B study of azacitidine, venetoclax and revumenib in newly diagnosed older adults with NPM1 mutated or KMT2A rearranged AML: interim results of dose escalation from the BEATAML consortium [abstract]

.

Hemasphere

.

2024

:

S134

.

37.

Issa

GC

,

Cuglievan

B

,

DiNardo

CD

, et al.

Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE) [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

58

.

38.

Fathi

A

,

Wang

E

,

Issa

G

, et al.

P504: updated data for ziftomenib in patients with NPM1-mutated relapsed or refractory acute myeloid leukemia

.

Hemasphere

.

2023

;

7

(

S3

):

e19161da

.

39.

Jabbour

E

,

Searle

E

,

Abdul-Hay

M

, et al.

A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

57

.

40.

Daver

N

,

Erba

H

,

Watts

JM

, et al.

First-in-human phase 1/2 study of the menin-MLL inhibitor DSP-5336 in patients with relapsed or refractory acute leukemia: updated results from dose escalation [abstract]

.

Hemasphere

.

2024

:

S132

.

41.

Lancet

J

,

Ravandi

F

,

Montesinos

P

, et al.

Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R/R) acute leukemia (AL): preliminary phase 1 data from the Covalent-101 study [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

2916

.

42.

Rausch

J

,

Dzama

MM

,

Dolgikh

N

, et al.

Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax

.

Haematologica

.

2023

;

108

(

10

):

2837

-

2843

.

43.

Kwon

MC

,

Thuring

JW

,

Querolle

O

, et al.

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias

.

Blood

.

2024

;

144

(

11

):

1206

-

1220

.

44.

Wei

A

,

Searle

E

,

Aldos

I

, et al.

Phase 1B study of the menin-KMT2A inhibitor JNJ-75276617 in combination with venetoclax and azacitidine in relapsed/refractory acute myeloid leukemia with alterations in KMT2A or NPM1 [abstract]

.

Hemasphere

.

2024

:

S133

.

45.

Perner

F

,

Stein

EM

,

Wenge

DV

, et al.

MEN1 mutations mediate clinical resistance to menin inhibition

.

Nature

.

2023

;

615

(

7954

):

913

-

919

.

46.

Soto-Feliciano

YM

,

Sánchez-Rivera

FJ

,

Perner

F

, et al.

A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition

.

Cancer Discov

.

2023

;

13

(

1

):

146

-

169

.

47.

Zhou

X

,

Zhang

L

,

Aryal

S

, et al.

Epigenetic regulation of non-canonical menin targets modulates menin inhibitor response in acute myeloid leukemia

.

Blood

.

2024

;

144

(

19

):

2018

-

2032

.

https://doi.org/10.3324/haematol.2024.285616.

48.

Hogeling

S

,

Lê

DM

,

La Rose

N

, et al.

Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617 impairs long-term proliferation and immune evasion in acute myeloid leukemia

.

Haematologica

.

Published online 19 December 2024

49.

Sparbier

CE

,

Gillespie

A

,

Gomez

J

, et al.

Targeting menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes

.

Nat Cell Biol

.

2023

;

25

(

2

):

258

-

272

.

50.

Heikamp

EB

,

Henrich

JA

,

Perner

F

, et al.

The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML

.

Blood

.

2022

;

139

(

6

):

894

-

906

.

51.

Barajas

JM

,

Rasouli

M

,

Umeda

M

, et al.

Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors

.

Blood

.

2024

;

143

(

7

):

619

-

630

.

52.

Schmidt

L

,

Heyes

E

,

Scheiblecker

L

, et al.

CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex

.

Leukemia

.

2019

;

33

(

7

):

1608

-

1619

.